Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 873

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 873
---
 aggregate amount of CHF [●] for the variable compensation of the Company’s executive officers. Furthermore the board proposes to set the grant of equity or equity linked instruments at a maximum aggregate amount of CHF [●] for the compensation of the Company’s executive officers and the board proposes the participation in the purchase of a run-off insurance policy for the Company’s executive officers, to be effective at the time of the merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for the financial year 2025. FOR AGAINST ABSTAIN 6. Approval of Contingent Value Rights (CVR) Agreement on an advisory vote The board proposes to approve the CVR Agreement in the sense of an advisory vote. The company intends to work towards selling its existing R&D assets under development, excluding the DOXA asset. FOR AGAINST ABSTAIN 7. Approval of Option and RSU Conversion on and advisory vote The board proposes to approve the planned conversion of outstanding options and RSUs issued by Kadimastem into equivalent securities with identical rights in Company at the time of the completion of the transactions contemplated by the Merger Agreement in the sense of an advisory vote. FOR AGAINST ABSTAIN Annex H-2 NLS PHARMACEUTICS LTD. Extraordinary Meeting of Shareholders [●], 2025 DETACH PROXY CARD HERE TO VOTE BY MAIL THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned, a shareholder of NLS Pharmaceutics Ltd., (the “Company”), hereby appoints KBT Treuhand AG Zurich as independent proxy, represented by David Maillard; or (full name and address) as proxy of the undersigned, with full power of substitution, for and in the name of the undersigned, to vote and otherwise act on behalf of the undersigned at the annual general meeting of shareholders of the Company to be held on [●], 2025, at the premises of [●], at [4] p.m. CET (10 a.m. EST), or at any adjournment(s) or postponement(s) thereof, with respect to all of the ordinary shares, of the Company (the “Shares”) which the undersigned would be entitled to vote, with all powers the undersigned would possess if personally present, provided said proxies are authorized and directed to vote as indicated with respect to the matter set forth below this Proxy. The undersigned herewith acknowledges all actions